Indeed, the IFN-induced upregulation of APM components improves anti-tumor specific CTL responses [117,118], and therefore represents a valuable strategy for the treatment of patients with transcriptional deregulated APM component expression. This evidence concerns the gene IFNA1 and neoplasm.